Research programme: orexin receptor antagonists - Rottapharm

Drug Profile

Research programme: orexin receptor antagonists - Rottapharm

Alternative Names: CR 5542

Latest Information Update: 15 Oct 2015

Price : $50

At a glance

  • Originator Rottapharm Madaus
  • Class Small molecules
  • Mechanism of Action Orexin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Anxiety disorders; Drug abuse; Obsessive-compulsive disorders; Sleep disorders

Most Recent Events

  • 15 Oct 2015 Early research in Drug abuse in Italy (unspecified route)
  • 01 Nov 2014 Early research and exploratory development of the programme is ongoing in Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top